Related Experiment Video

Updated: Jun 8, 2026

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

Diagnostic value of MPO plasma levels in patients admitted for suspected myocardial infarction

Volker Rudolph1, Britta U Goldmann, Constantin Bös

  • 1Department of General and Interventional Cardiology, University Heart Center Hamburg and Cardiovascular Research Center Hamburg, Germany. v.rudolph@uke.de

International Journal of Cardiology
|September 18, 2010
PubMed
Abstract

Insights

Myeloperoxidase (MPO) shows promise as a diagnostic marker for acute myocardial infarction (AMI) in chest pain patients. Elevated MPO levels aid in AMI diagnosis, especially within the first two hours of symptom onset.

Area of Science:

  • Cardiology
  • Biomarkers
  • Emergency Medicine

Background:

  • Myeloperoxidase (MPO) is recognized for its role in atherosclerosis and as a prognostic indicator in cardiovascular disease.
  • Previous research on MPO in cardiovascular disease was primarily retrospective and single-time point assessments.
  • This study prospectively evaluates MPO's prognostic value through consecutive measurements in chest pain patients.

Purpose of the Study:

  • To prospectively assess the diagnostic and prognostic information of myeloperoxidase (MPO) in patients presenting with chest pain.
  • To evaluate MPO's utility in diagnosing acute myocardial infarction (AMI), particularly when other markers are negative or in early stages.

Main Methods:

  • Plasma MPO levels were measured in 274 consecutive patients admitted to the emergency room for chest pain.
  • Comparison of MPO levels between patients diagnosed with AMI and those without.
  • Assessment of MPO's diagnostic performance (sensitivity, negative predictive value) against troponin I (TNI).

Main Results:

  • Patients diagnosed with AMI exhibited significantly higher MPO levels compared to non-AMI patients.
  • MPO levels were elevated in AMI patients even with negative troponin I (TNI) results.
  • MPO demonstrated a sensitivity of 80.0% and NPV of 85.5% for AMI diagnosis.
  • In patients with symptom onset ≤ 2 hours, MPO sensitivity was 95.8% (NPV 95.6%), outperforming TNI (sensitivity 50.0%, NPV 73.3%).

Conclusions:

  • Myeloperoxidase (MPO) is a valuable diagnostic marker in acute coronary syndromes.
  • The additive diagnostic information from MPO is most significant in patients presenting early after symptom onset (within 2 hours).
  • MPO can aid in the early diagnosis of acute myocardial infarction, especially when TNI is negative or during the initial hours of symptoms.

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...